Law360, New York ( August 29, 2014, 9:51 AM EDT) -- As the ongoing Ebola virus outbreak in West Africa continues unabated, the world has looked on and cheered as experimental ZMapp anti-Ebola virus antibodies developed by MappBio — a biotech startup in San Diego — have shown initial indications of being able to stop the progression of Ebola virus infection. One consideration that has not gotten much press-ink in the stories surrounding ZMapp is the relevance of U.S. patent law to this startling and inspiring technology....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.